Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 70Neoplasm Metastasis 26Stomach Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Neoplasms 8Brain Neoplasms 8Adenocarcinoma 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 3Recurrence 3Pancreatic Neoplasms 3HER2-positive Breast Cancer 3Advanced Solid Tumor 3Sarcoma 2Prostatic Neoplasms 2Neoplasm, Residual 2Meningeal Carcinomatosis 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Breast Cancer With Brain Metastasis 2Advanced Breast Cancer 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × trastuzumab deruxtecan × Clear all
NCT07340164 2026-04-20

TROY

Yonsei University

Phase 2 Recruiting
116 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT07015697 2026-03-20

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Daiichi Sankyo

Phase 1 Recruiting
76 enrolled

Recurrence

NCT05704829 2025-11-19

ADAPTHER2-IV

West German Study Group

Phase 2 Active not recruiting
402 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡